| Name | Title | Contact Details |
|---|
As one of Western New York`s first HMOs, Independent Health covers over 365,000 people here and across the country with more than 100 plans, services and products. If you have any questions about your Independent Health account, feel free to contact us through one of the following links: Members - Contact Member Services for questions regarding your Independent Health plan, benefits, doctor information, etc. You may also use this link if you are having problems logging into our online system. FSA Members - Contact the FSA Department for questions regarding your FSA Account information. You may also use this link if you are having problems logging into our online system. Healthcare Professionals/Providers - Provider or Health Care offices may contact Provider Relations for billing inquiries, requests to become participating providers, or for general questions. Employers - Contact Employer Relations Brokers - Contact Broker Sales
Clear Catheter Systems is a Bend, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Specialized Dental Partners provides a supported integrated care model that will help you attract more patients, provide next level care, and realize the benefits of retirement while you are still building and benefitting from your career.
Albion Laboratories is a Clearfield, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.